• Contact us: 01476 247 007
    Breast Implants Safety Concerns – the Importance of Post-Marketing SurveillanceBreast Implants Safety Concerns – the Importance of Post-Marketing SurveillanceBreast Implants Safety Concerns – the Importance of Post-Marketing SurveillanceBreast Implants Safety Concerns – the Importance of Post-Marketing Surveillance
    • How can we help
      • Pharmacovigilance
        • National contact person for pharmacovigilance – post Brexit
        • Pharmacovigilance Standard Operating Procedure Audits
        • Post Marketing Pharmacovigilance Support
        • Clinical Trial Pharmacovigilance Support
        • EU QPPV Provision
        • Quality & Compliance
        • Risk Assessment and Management
        • Signal Detection and Management
      • Medical Writing
      • Patient Information
      • Regulatory
      • Market Authorisation Holding
    • Brexit
    • Our Partners
      • Marti Farm
      • Affiliates
      • Medilink
      • External Team
    • News
    • Get in touch
    Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC ) 11-15 March 2019
    4th April 2019
    Yellow fever vaccine
    22nd July 2019

    Breast Implants Safety Concerns – the Importance of Post-Marketing Surveillance

    4th April 2019

    Recently, (24 March 2019), the FDA have started to scrutinise the safety of breast implants, which brings into focus the importance of post-marketing surveillance in patient safety.

    Back in 1992, the FDA banned silicone gel implants because of fears that they may cause breast cancer, lupus, chronic fatigue syndrome and other disorders. Then in 2006, the FDA agreed to re-introduce silicone implants with the caveat that all manufacturers track recipients over a long period to monitor any adverse side-effects.

    The position has been that implants are safe, as long as patients realise that they can have complications. But, recently there has been confirmation of a link between textured implants and breast implant-associated anaplastic large cell lymphoma. Furthermore, there has been a continuation of women complaining about other ailments like muscle pain, rheumatoid arthritis and immune system disorder.

    Late last month (March 2019), it was reported that the FDA had issued warning letters to two breast implant manufacturers as they had failed to comply with these requirements and were in violation of the pre-market approval order. The regulator was concerned about the low recruitment, poor data and low follow-up rates in the post-approval studies. The FDA have given both firms 15 working days to respond. This marks a more aggressive approach and shows how seriously the FDA is approaching patient safety issues. They have developed a National Breast Implant Registry to aid in the collection of data to help understand the long term safety and risks associated with breast implants.

    https://www.thepsf.org/research/registries/nbir

    Share

    Related posts

    MHRA post-transition period information from Pure Drug Safety
    3rd September 2020

    MHRA post-transition period information


    Read more
    What happens after Brexit for Pharmacovigilance and Regulatory?
    12th February 2020

    What happens after Brexit for Pharmacovigilance and Regulatory?


    Read more
    Pharmacovigilance (QPPV) provision post-Brexit
    7th February 2020

    Pharmacovigilance (QPPV) provision post-Brexit


    Read more

    PLEASE NOTE OUR NEW PHONE NUMBER AS OF 1st JUNE 2021
    Call our team +44(0) 1476 247 007
    email info@puredrugsafety.com



    Sign up for our newsletter

    Pure Drug Safety Ltd

    Pure Drug Safety Ltd · 1 year ago
    @PureDrugSafety



    Many clients have already put their NCPP in place with us here at PDS and are ready for January 2022.

    Read more 👉 https://t.co/6mnM9Dzoma

    #NationalContactPerson #KnowledgeablePerson #ExperiencedQppv https://t.co/rS2W4PZbDv

    View on Twitter


    0

    0

    © 2019 - 2023 Pure Drug Safety.
    As of 1st June 2021 NEW OFFICE & REGISTERED ADDRESS: BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Pure Drug Safety Limited is a company registered in England and Wales. Registered Company Number 7702236. VAT Registered Number 117 966 288
    For our GDPR and Privacy Policy click here
    Designed by Gather Creative | Content managed by Tailored Marketing Solutions | Built + Hosted by GIGER MEDIA